Posted on

curve cbd

CBD From a Retailer and Payor Perspective (Rhyee)

2,500) we were surprised to see that nearly 7% of respondents in January 2019 reported using CBD as a supplement. This strong consumer interest is validated by the growing number of brands and form factors that are now available through increasingly diverse retail channels, including Amazon, Sephora and Neiman Marcus. That said, consumption of CBD on-premise will likely take longer, given regulatory uncertainty. And, while our analysis primarily focuses on consumer staples applications for CBD, it is interesting to see a growing number of specialty apparel brands embrace hemp as a sustainable textile.

Healthcare: Payor Perspective: Generally speaking, managed care does not cover OTC products, with the same being true for Medicare and Medicaid. Based on our conversations with a number of payors, whether CBD oils will be covered as a medical benefit by government sponsored health programs is determined by the Center for Medicare and Medicaid Services (CMS) and state governments. Currently, CBD products are not a covered benefit, or an extra benefit, that has been approved by CMS or states, and it isn’t known at this time whether CMS or states governments are considering reimbursement for CBD products. Separately, Payors noted three factors complicating commercial coverage of CBD oils, including (1) legal issues, as CBD oils derived from THC (cannabis) isn’t legal if it contains equal to or more than 0.3% THC; (2) lack of regulation by the FDA; and (3) its availability as an OTC medication.

Herein, we offer a detailed look at category brand and pricing architecture in the U.S. CBD market today, as well as detailed discussions of 19 public and private operators that currently have exposure to the category.

Regulatory Outlook (Eric Assaraf – Cowen Washington Research Group)
The 2018 Farm Bill declassifies industrial hemp as a Schedule I substance, shifts regulatory authority from the DEA to the Department of Agriculture, and provides autonomy for states to regulate the industry. However, the new law does not change the FDA’s oversight authority over CBD products and FDA Commissioner Scott Gottlieb has made it clear that his agency will continue to step in when certain health claims are made. Additionally, FDA has stated that CBD cannot be added to food products sold across state lines or marketed as a dietary supplement, regardless of whether it is hemp-derived. The FDA will explore new pathways for CBD to be sold legally; however, it seems clear that there will be a period of regulatory uncertainty over CBD products at the state and federal level.

$600 mm and $2 bn. By 2025, we believe CBD offerings could conservatively generate $16 bn in retail sales (assuming a

Global Landscape (Azer)
While the global regulatory landscape varies, the CBD category outside of the U.S. has been evolving rapidly, with more change likely to come with the WHO’s current evaluation of CBD, as well as its recent addition to the EU’s Novel Food Catalogue. In Europe, CBD products are now widely available in markets like the U.K., Italy and Switzerland, though regulations vary with Italy allowing for “cannabis light” products, with allowable THC of as much as 0.6%, while in Switzerland CBD products can have as much as 1% THC, and are classified as a tobacco substitute. In Latin America, hemp has been in production since the 1500s is also rapidly expanding their regulatory frameworks around marijuana and hemp. Canadian licensed producers have been actively entering the market in Latin America to capitalize on this evolving opportunity, including Canopy Growth, Tilray, Aurora and Cronos.

40% increase in consumer incidence, to 10%, and spend of less than $2 / day). Our bottom-up analysis anticipates a diverse category, that is still led by traditional health & wellness form factors (e.g., $6.4 bn in nutraceuticals, and $4 bn in topicals). And, while likely smaller, we also expect categories like food, beverages, beauty and vapor to all generate sales between

Curve cbd

At larger scales, mixing is less efficient and more energy intensive. Non-uniform mixing causes temperature and concentration gradients to form in the vessel, for example, areas close to the walls of the vessel will be colder than at the centre of the vessel. This leads to areas where, simultaneously within the same vessel, material is both spontaneously precipitating and re-dissolving.

In a NiTech ® continuous crystallizer, the combination of optimal mixing, enhanced heat transfer and the addition of seeds, the operator can keep the CBD concentration in solution inside the metastable zone throughout the crystallization process (see Fig 2.).

Precipitation is rapid and forms a large quantity of small particles, as rate of formation of new solids greatly exceeds the rate of crystal growth. Also, due to the speed of precipitation, other components become entrapped in the precipitate, resulting in a lower purity material; these can include the solvent as well as other components present in the solvent system at the time.

There are several steps required to take the cannabis biomass ‘from crop to crystal’. These steps will vary depending on the user’s preferred extraction method, but typically the steps are as follows:

Mass transfer

We hope you have found this page useful. We have explained the science behind crystallization and how it applies to CBD isolate production. We also explained how CBD isolate manufacturers can overcome the limitations of established, batch-based crystallization equipment through the application of NiTech’s proprietary continuous crystallizer.

Although the phase of the product is the same (i.e. a solid), the characteristic of the product and the mechanism by which it is formed is different between the two processes.

It is possible to attempt seeded, cooling crystallization in batch stirred tanks; like the operation of a NiTech® continuous crystallizer. B/R Instrument’s blog provides a comprehensive explanation of this process: how to crystallize cbd

What is seeded cooling crystallization?

Cannabidiol (CBD) isolate is hemp-industry nomenclature for crystalline cannabidiol. It is cannabidiol in its purest form and its appearance (when pure) is that of an off-white crystalline solid. It is referred to as CBD isolate because CBD is one component of a multi-component extract that has been ‘isolated’ from all the others.

For these reasons, although quick and easy, precipitation is not an effective or desirable means of isolating a compound from a solution due to poor process performance.